Urinary Cancer
Alliance / A031702
Official Title: Testing the effectiveness of two immunotherapy drugs (nivolumab and ipilimumab) with one anti-cancer targeted drug (cabozantinib) for rare genitourinary tumors
Study Purpose: To test the good and bad effects of the drugs cabozantinib, nivolumab, and ipilimumab in rare genitourinary cancers that have no standard treatment options.The doctors hope to learn if the study drugs will stabilize or shrink the cancer.
Status:
Recruiting